Ophthalmic Drugs Market, By Formulation Type (Injectables, Gels, Ointments, Eye Drops, and Sustained Release), By Therapeutic Area, By Application, By Route of Administration, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4783
|
Published Date
February 2026
|
Pages
321
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
The Ophthalmic Drugs Market size was valued at US$40,456.34 Million in 2024, expanding at a CAGR of 8.45% from 2025 to 2032.
Ophthalmic drugs are specialized medical products designed to help healthcare professionals diagnose, treat, prevent, and manage eye diseases affecting the eye and surrounding tissues. These drugs deliver targeted, localized treatment through various methods—such as eye drops, gels, ointments, inserts, and injections—allowing precise medication delivery while minimizing systemic side effects. Ophthalmic drugs address a wide range of conditions, including glaucoma, dry eye disease, conjunctivitis, uveitis, agerelated macular degeneration, diabetic retinopathy, infections, and inflammation. They contain active pharmaceutical ingredients such as antibiotics, antivirals, antifungals, antiinflammatory agents, antiglaucoma medications, and biologics. Strict sterility and safety standards are maintained during development and production to ensure the protection of sensitive ocular tissues.
The global burden of eye conditions is a major public health concern, with at least 2.2billion people worldwide living with vision impairment or blindness, many of whom could benefit from improved treatment access and care, according to the World Health Organization. This widespread prevalence is driving demand for effective ophthalmic therapies and has led governments and health systems to prioritize eye care services and drug approvals to improve prevention and treatment outcomes globally.
Ophthalmic Drugs Market- Market Dynamics
Increasing Prevalence of Eye Diseases
The ophthalmic drugs market is experiencing significant growth due to the rising prevalence of eye diseases worldwide. Conditions such as glaucoma, cataracts, age-related macular degeneration, diabetic retinopathy, dry eye disease, and infectious conjunctivitis are increasing in occurrence, driving sustained demand for effective treatments. The global rise in eye disorders is fueled by several factors, including population aging, increasing rates of diabetes, prolonged screen exposure, urbanization, and environmental pollution. This growing need for both prescription and over-the-counter ophthalmic drugs reflects the importance of early diagnosis, long-term treatment, and ongoing disease management, supporting continuous market expansion in both developed and emerging regions.
For example, according to the World Health Organization (WHO), at least 2.2 billion people worldwide suffer from near- or distance-vision impairment, with 1 billion cases caused by preventable or untreated conditions. This global burden underscores the critical demand for advanced ophthalmic therapies and reinforces government and healthcare initiatives to improve access to eye care.
Ophthalmic Drugs Market- Segmentation Analysis:
By Application
In 2024, the anti-inflammatory segment holds a significant revenue share in the global ophthalmic drugs market. Anti-inflammatory ophthalmic medications, including corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), are widely used by doctors to treat a variety of eye conditions such as postoperative inflammation, uveitis, and allergic conjunctivitis. The rising prevalence of eye diseases—driven by aging populations, increasing rates of eye surgeries, and the growth of chronic conditions like glaucoma and diabetic retinopathy—has created strong demand for these treatments. According to the U.S. Centers for Disease Control and Prevention (CDC), over 3.4 million adults in the United States experienced vision impairment or severe eye disorders in 2023, underscoring the growing need for effective ophthalmic therapies. Innovations in formulation technology, including preservative-free eye drops and sustained-release delivery systems, have improved both the safety and efficacy of anti-inflammatory treatments, while enhancing patient adherence. These combined clinical and technological developments continue to drive revenue growth for the anti-inflammatory category within the ophthalmic drugs market.
By Route of Administration
By route of administration, the topical segment dominates the market due to its clinical effectiveness and convenience. Topical ophthalmic drugs deliver medication directly to the eye surface, providing immediate symptom relief and targeted treatment, which makes them the preferred choice in most clinical settings. This segment maintains revenue leadership because topical treatments are highly effective for managing common eye conditions such as dry eye syndrome, allergic conjunctivitis, and postoperative inflammation. The U.S. Food and Drug Administration (FDA) reports that the approval of new topical ophthalmic formulations increased by 15% between 2022 and 2023, reflecting advancements in preservative-free solutions and improved delivery systems that enhance patient comfort and adherence. These factors collectively sustain the growth of the topical ophthalmic drugs market, making it a cornerstone segment in ophthalmic therapy worldwide.
Ophthalmic Drugs Market- Geographical Insights
North America holds the largest revenue share in the ophthalmic drugs market over the projected period. This strong position is driven by the rising prevalence of eye diseases and the support of beneficial government healthcare programs and reimbursement frameworks across the region. North America, particularly the United States and Canada, has a developed healthcare system with high levels of spending on eye care, which supports early diagnosis and advanced treatment adoption. The market expands due to a growing number of individuals requiring eye care and the increasing volume of ophthalmic treatment procedures. The demand in the U.S. and Canada is further strengthened by the aging population, as older adults have a higher incidence of vision disorders, and by the increasing rate of diabetes, which leads to diabetic eye conditions such as retinopathy that require ongoing treatment.
Globally, the ophthalmic drugs market was valued at approximately USD41.39billion in 2025 and is projected to reach USD79.44billion by 2033, underscoring widespread demand for effective eye care therapies driven by rising vision impairment and supportive healthcare policies in many countries.North America accounted for around 42.5% of the global ophthalmic drugs market in 2025, reflecting both high disease prevalence and strong healthcare infrastructure in the region.
Ophthalmic Drugs Market- Competitive Landscape:
The ophthalmic drugs market operates in a highly competitive environment, shaped by major diversified pharmaceutical companies, specialized vision-care firms, and the rapidly evolving biologics sector, particularly anti-VEGF therapies. Market dynamics are further influenced by mergers and acquisitions, licensing agreements, and increasing competition from generic and biosimilar products. Leading global players, including AbbVie (Allergan), Alcon, Bausch + Lomb, Regeneron (in collaboration with Bayer for Eylea), Novartis, Roche, Bayer, and Santen, maintain their strong positions through comprehensive product portfolios, extensive distribution networks, and robust research and development programs covering both small-molecule and biologic ophthalmic treatments.
Recent Developments:
- In October 2025, Santen Pharmaceutical Co., Ltd. launched SETANEO® Ophthalmic Solution 0.002% (generic name: sepetaprost) in Japan for the treatment of glaucoma and ocular hypertension. Sepetaprost, a bicyclic prostaglandin derivative, binds to FP and EP3 receptors to increase aqueous humor outflow and reduce intraocular pressure. The product received marketing authorization approval in August 2025, following Phase III clinical trials conducted in Japan, with the application initially submitted in September 2024.
- In December 2025, Amneal Pharmaceuticals, Inc. announced that the U.S. FDA approved its cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation in single-use vials. This product serves as a generic equivalent to RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, a registered trademark of Allergan, an AbbVie company.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL OPHTHALMIC DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Roche (Genentech, Inc.)
- Regeneron Pharmaceuticals, Inc.
- Bausch Health Companies, Inc.
- Merck & Co., Inc.
- Novartis AG
- Coherus BioSciences, Inc.
- AbbVie, Inc. (Allergan)
- Pfizer, Inc.
- Bayer AG
- Santen Pharmaceutical Co., Ltd.
- Alcon
- Nicox
GLOBAL OPHTHALMIC DRUGS MARKET, BY FORMULATION TYPE- MARKET ANALYSIS, 2019 - 2032
- Injectables
- Gels
- Ointments
- Eye Drops
- Sustained Release
GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032
- Retinal Disorders
- Cataract Surgery
- Allergic Conjunctivitis
- Infectious Diseases
- Ocular Hypertension
GLOBAL OPHTHALMIC DRUGS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032
- Antiviral
- Antibiotic
- Anti-Inflammatory
- Glaucoma
- Dry Eye
GLOBAL OPHTHALMIC DRUGS MARKET, ROUTE OF ADMINISTRATION - MARKET ANALYSIS, 2019 - 2032
- Topical
- Subconjunctival
- Intravitreal
- Systemic
- Periocular
GLOBAL OPHTHALMIC DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Ophthalmic Drugs Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Ophthalmic Drugs Market Snippet by Formulation Type
2.1.2. Ophthalmic Drugs Market Snippet by Therapeutic Area
2.1.3. Ophthalmic Drugs Market Snippet by Application
2.1.4. Ophthalmic Drugs Market Snippet by Route of Administration
2.1.5. Ophthalmic Drugs Market Snippet by Country
2.1.6. Ophthalmic Drugs Market Snippet by Region
2.2. Competitive Insights
3. Ophthalmic Drugs Key Market Trends
3.1. Ophthalmic Drugs Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Ophthalmic Drugs Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Ophthalmic Drugs Market Opportunities
3.4. Ophthalmic Drugs Market Future Trends
4. Ophthalmic Drugs Therapeutic Area Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Ophthalmic Drugs Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Ophthalmic Drugs Market Landscape
6.1. Ophthalmic Drugs Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Ophthalmic Drugs Market – By Formulation Type
7.1. Overview
7.1.1. Segment Share Analysis, By Formulation Type, 2024&2032 (%)
7.1.2. Injectables
7.1.3. Gels
7.1.4. Ointments
7.1.5. Eye Drops
7.1.6. Sustained Release
8. Ophthalmic Drugs Market – By Therapeutic Area
8.1. Overview
8.1.1. Segment Share Analysis, By Therapeutic Area, 2024&2032 (%)
8.1.2. Retinal Disorders
8.1.3. Cataract Surgery
8.1.4. Allergic Conjunctivitis
8.1.5. Infectious Diseases
8.1.6. Ocular Hypertension
9. Ophthalmic Drugs Market – By Application
9.1. Overview
9.1.1. Segment Share Analysis, By Application, 2024&2032 (%)
9.1.2. Antiviral
9.1.3. Antibiotic
9.1.4. Anti-Inflammatory
9.1.5. Glaucoma
9.1.6. Dry Eye
10. Ophthalmic Drugs Market – By Route of Administration
10.1. Overview
10.1.1. Segment Share Analysis, By Route of Administration, 2024&2032 (%)
10.1.2. Topical
10.1.3. Subconjunctival
10.1.4. Intravitreal
10.1.5. Systemic
10.1.6. Periocular
11. Ophthalmic Drugs Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2024&2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
11.2.4. North America Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.2.7. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.2.8.3. U.S. Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.2.8.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.2.8.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.2.8.6. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.2.9.3. Canada Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.2.9.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.2.9.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.2.9.6. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.3. Europe
11.3.1. Overview
11.3.2. Ophthalmic Drugs Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
11.3.4. Europe Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.3.7. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.3.8.3. Germany Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.3.8.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.3.8.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.3.8.6. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.3.9.3. UK Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.3.9.4. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.3.9.5. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.3.9.6. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.3.10.3. France Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.3.10.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.3.10.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.3.10.6. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.3.11.3. Italy Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.3.11.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.3.11.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.3.11.6. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.3.12.3. Spain Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.3.12.4. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.3.12.5. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.3.12.6. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.3.13.3. The Netherlands Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.3.13.4. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.3.13.6. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.3.14.3. Sweden Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.3.14.4. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.3.14.5. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.3.14.6. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.3.15.3. Russia Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.3.15.4. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.3.15.5. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.3.15.6. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.3.16.3. Poland Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.3.16.4. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.3.16.5. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.3.16.6. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.3.17.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Ophthalmic Drugs Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
11.4.4. APAC Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.4.5. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.4.6. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.4.7. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.4.8.3. China Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.4.8.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.4.8.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.4.8.6. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.4.9.3. India Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.4.9.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.4.9.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.4.9.6. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.4.10.3. Japan Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.4.10.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.4.10.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.4.10.6. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.4.11.3. South Korea Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.4.11.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.4.11.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.4.11.6. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.4.12.3. Australia Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.4.12.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.4.12.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.4.12.6. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.4.13.3. Indonesia Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.4.13.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.4.13.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.4.13.6. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.4.14.3. Thailand Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.4.14.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.4.14.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.4.14.6. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.4.15.3. PhilippinesMarket Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.4.15.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.4.15.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.4.15.6. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.4.16.3. Rest of APAC Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.4.16.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.4.16.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Ophthalmic Drugs Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
11.5.4. LATAM Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.5.5. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.5.6. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.5.7. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.5.8.3. Brazil Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.5.8.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.5.8.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.5.8.6. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.5.9.3. Mexico Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.5.9.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.5.9.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.5.9.6. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.5.10.3. Argentina Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.5.10.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.5.10.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.5.10.6. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.5.11.3. Colombia Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.5.11.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.5.11.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.5.11.6. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.5.12.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Ophthalmic Drugs Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
11.6.4. MEA Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.6.5. MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.6.6. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.6.7. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.6.8.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.6.9. UAE
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.6.9.3. UAE Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.6.9.4. UAE Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.6.9.5. UAE Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.6.9.6. UAE Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.6.10.3. Israel Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.6.10.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.6.10.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.6.10.6. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.6.11.3. Turkey Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.6.11.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.6.11.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.6.11.6. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.6.12.3. Algeria Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.6.12.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.6.12.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.6.12.6. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.6.13.3. Egypt Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.6.13.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.6.13.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.6.13.6. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
11.6.14.3. Rest of MEA Market Size and Forecast, By Formulation Type, 2019 - 2032 (US$ Billion)
11.6.14.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Billion)
11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Billion)
11.6.14.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Billion)
12. Key Vendor Analysis- Ophthalmic Drugs
12.1. Competitive Dashboard
12.1.1. Competitive Benchmarking
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Roche (Genentech, Inc.)
12.2.2. Regeneron Pharmaceuticals, Inc.
12.2.3. Bausch Health Companies, Inc.
12.2.4. Merck & Co., Inc.
12.2.5. Novartis AG
12.2.6. Coherus BioSciences, Inc.
12.2.7. AbbVie, Inc. (Allergan)
12.2.8. Pfizer, Inc.
12.2.9. Bayer AG
12.2.10. Santen Pharmaceutical Co., Ltd.
12.2.11. Alcon
12.2.12. Nicox
13. 360 Degree Analyst View
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL OPHTHALMIC DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Roche (Genentech, Inc.)
- Regeneron Pharmaceuticals, Inc.
- Bausch Health Companies, Inc.
- Merck & Co., Inc.
- Novartis AG
- Coherus BioSciences, Inc.
- AbbVie, Inc. (Allergan)
- Pfizer, Inc.
- Bayer AG
- Santen Pharmaceutical Co., Ltd.
- Alcon
- Nicox
GLOBAL OPHTHALMIC DRUGS MARKET, BY FORMULATION TYPE- MARKET ANALYSIS, 2019 - 2032
- Injectables
- Gels
- Ointments
- Eye Drops
- Sustained Release
GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032
- Retinal Disorders
- Cataract Surgery
- Allergic Conjunctivitis
- Infectious Diseases
- Ocular Hypertension
GLOBAL OPHTHALMIC DRUGS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032
- Antiviral
- Antibiotic
- Anti-Inflammatory
- Glaucoma
- Dry Eye
GLOBAL OPHTHALMIC DRUGS MARKET, ROUTE OF ADMINISTRATION - MARKET ANALYSIS, 2019 - 2032
- Topical
- Subconjunctival
- Intravitreal
- Systemic
- Periocular
GLOBAL OPHTHALMIC DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
